Jiangsu Bioperfectus Technologies Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 37.23%

Jiangsu Bioperfectus Technologies Co Ltd (688399) has an Asset Resilience Ratio of 37.23% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Jiangsu Bioperfectus Technologies Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥1.36 Billion
≈ $198.80 Million USD Cash + Short-term Investments

Total Assets

CN¥3.65 Billion
≈ $533.91 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Jiangsu Bioperfectus Technologies Co Ltd's Asset Resilience Ratio has changed over time. See Jiangsu Bioperfectus Technologies Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Bioperfectus Technologies Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jiangsu Bioperfectus Technologies Co Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.36 Billion 37.23%
Total Liquid Assets CN¥1.36 Billion 37.23%

Asset Resilience Insights

  • Very High Liquidity: Jiangsu Bioperfectus Technologies Co Ltd maintains exceptional liquid asset reserves at 37.23% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Bioperfectus Technologies Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Bioperfectus Technologies Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
Biotechnology 6.52%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Annual Asset Resilience Ratio for Jiangsu Bioperfectus Technologies Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Jiangsu Bioperfectus Technologies Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 30.42% CN¥1.14 Billion
≈ $166.50 Million
CN¥3.74 Billion
≈ $547.27 Million
+12.64pp
2023-12-31 17.79% CN¥694.81 Million
≈ $101.67 Million
CN¥3.91 Billion
≈ $571.63 Million
-2.96pp
2022-12-31 20.75% CN¥1.01 Billion
≈ $148.51 Million
CN¥4.89 Billion
≈ $715.71 Million
+2.94pp
2021-12-31 17.81% CN¥623.33 Million
≈ $91.21 Million
CN¥3.50 Billion
≈ $512.06 Million
+4.72pp
2020-12-31 13.09% CN¥298.22 Million
≈ $43.64 Million
CN¥2.28 Billion
≈ $333.30 Million
-37.21pp
2019-12-31 50.31% CN¥580.70 Million
≈ $84.98 Million
CN¥1.15 Billion
≈ $168.92 Million
--
pp = percentage points

About Jiangsu Bioperfectus Technologies Co Ltd

SHG:688399 China Biotechnology
Market Cap
$605.68 Million
CN¥4.14 Billion CNY
Market Cap Rank
#11420 Global
#3266 in China
Share Price
CN¥49.35
Change (1 day)
-2.20%
52-Week Range
CN¥46.53 - CN¥84.90
All Time High
CN¥419.88
About

Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, … Read more